Artemis Investment Management LLP acquires $13.41M position in Johnson & Johnson (NYSE:JNJ)


Artemis Investment Management LLP purchased a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating ) during the first quarter, Holdings Channel reports. The firm purchased 75,814 shares of the company’s stock, valued at approximately $13,408,000.

Several other institutional investors have also made changes to their positions in the company. Ellsworth Advisors LLC raised its position in shares of Johnson & Johnson by 1.7% in the first quarter. Ellsworth Advisors LLC now owns 9,710 shares of the company’s stock worth $1,786,000 after buying an additional 162 shares in the last quarter. Berkshire Bank raised its position in shares of Johnson & Johnson by 2.2% in the first quarter. Berkshire Bank now owns 14,435 shares of the company’s stock valued at $2,558,000 after buying an additional 306 shares in the last quarter. Zhang Financial LLC lifted its position in shares of Johnson & Johnson by 265.0% in the first quarter. Zhang Financial LLC now owns 36,771 shares of the company’s stock valued at $6,517,000 after buying an additional 26,697 shares in the last quarter. apricus wealth LLC raised its position in shares of Johnson & Johnson by 13.1% in the first quarter. apricus wealth LLC now owns 16,046 shares of the company’s stock valued at $2,951,000 after buying an additional 1,854 shares in the last quarter. Finally, Western Pacific Wealth Management LP raised its position in shares of Johnson & Johnson by 3.0% in the first quarter. Western Pacific Wealth Management LP now owns 2,605 shares of the company’s stock valued at $461,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s shares.

In other news, insider William Hait sold 29,699 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. Disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,161 shares of company stock valued at $13,895,302. Insiders own 0.35% of the company’s stock.

A number of equities research analysts recently commented on the company. Citigroup decreased their target price on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Goldman Sachs Group boosted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Raymond James boosted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Morgan Stanley boosted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $190.67, according to MarketBeat .

Shares of NYSE JNJ opened at $178.28 on Friday. The business’s 50-day moving average is $176.89, and its two-hundred-day moving average is $174.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39, and a quick ratio of 1.14. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The stock has a market capitalization of $469.13 billion, a P/E ratio of 24.03, a PEG ratio of 3.53 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJ – Get Rating ) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The firm had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter a year ago, the firm posted $2.59 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

Johnson & Johnson Profile (Get rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various products in the field of health care worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get the Rating ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.